Navigation Links
Scientists to study the role genes play in treating TB
Date:10/25/2012

The University of Liverpool has been awarded funding to determine whether differences in our genes determine how patients respond to drugs used to treat Tuberculosis (TB) in Sub-Saharan Africa.

Professor Andrew Owen, from the University's Department of Molecular and Clinical Pharmacology, is part of an international research team that will explore why some patients respond positively to anti-TB drug treatment while in other patients the treatments fail or the patients experience toxicity. In patients with HIV/AIDS the percentage of patients that are not cured by therapy is even higher.

TB is the second leading cause of death from an infectious disease worldwide after HIV/AIDS. In 2010 there were 8.8 million new cases of TB and 1.1 million deaths, including 350,000 deaths from TB among people with HIV. In Sub-Saharan Africa TB poses a major public health problem and is the leading killer of people living with HIV, causing one quarter of all deaths.

Professor Owen said: "There is a much greater understanding of genes which affect how we react and respond to drugs used in other diseases such as HIV than there is for TB. This project will study the genes of patients being treated with the four main anti-TB drugs, and also with a new drug which is in development, using clinical trial sites in Benin, Senegal and South Africa. The study aims to explore and determine genetic differences which affect the effectiveness and reaction to anti-TB drugs. It is funded through the H3Africa project which is led by African scientists and one of its aims is to foster capacity-building for research in Sub Saharan Africa."

The standard treatment for TB is a six-month course of four drugs taken daily for two months, followed by two drugs taken for a four-month period but as many as 10 per cent of patients do not respond to this treatment. Patients who have been treated with anti-TB drugs have an increased risk of spreading a strain of TB that is resistant to drug treatments.

TB is caused by bacteria (Mycobacterium tuberculosis) that often affect the lungs. It is spread from person to person through the air. When people with lung TB cough, sneeze or spit, they propel the TB germs into the air and only a few of these germs need to be inhaled for another person to become infected.

People infected with TB bacteria have a 10% lifetime risk of falling ill with TB. However people with compromised immune systems, such as people living with HIV, malnutrition or diabetes, or those who use tobacco, have a much higher risk of falling ill.


'/>"/>
Contact: Sarah Stamper
sarah.stamper@liv.ac.uk
01-517-943-044
University of Liverpool
Source:Eurekalert

Related medicine news :

1. Kessler Foundation scientists awarded New Jersey grants for brain injury research
2. Scientists Focus on Factors Behind Asthma Attacks
3. Einstein-Montefiore scientists awarded 2 NCI Provocative Questions grants
4. Leading stem cell scientists to focus on diabetes, eye diseases at Cedars-Sinai symposium
5. Diets High in Fructose May Harm Liver in Some, Scientists Warn
6. Cardiff scientists bid to develop anthrax vaccine to counteract world bioterrorism threat
7. Scripps Research Institute scientists show protein linked to hunger also implicated in alcoholism
8. Scientists Spot 5 Genes That Help Shape Faces
9. Eight scientists honored in first annual Golden Goose Awards
10. Scientists Map Genetic Blueprint of Heart
11. Scientists use sound waves to levitate liquids, improve pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San ... using cutting-edge Oventus O2Vent technology. As many as 18 million Americans are ... cessation in breathing. Oral appliances can offer significant relief to about 75 percent ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company ... of today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every ... meet the highest standard. , These products are also: Gluten Free, Non-GMO, ...
(Date:10/12/2017)... ... , ... The American College of Medical Informatics (ACMI) will present the 2017 ... Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium is ... pioneer in the field of medical informatics, this prestigious award is presented to an ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about ... intend to develop to enable prevention of a major side effect of chemotherapy ... especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader in ... 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced ... 2017. , The annual award competition recognizes editorial and design excellence across a range ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... Oct. 12, 2017 West Pharmaceutical Services, ... solutions for injectable drug administration, today announced that it ... opens on Thursday, October 26, 2017, and will follow ... business expectations at 9:00 a.m. Eastern Time. To participate ... (International). The conference ID is 94093362. ...
(Date:10/10/2017)... 10, 2017  NDS received FDA 510(k) clearance in May 2017 ... display stand specifically designed for endoscopy environments. An innovative secondary monitor ... clinical solution to support the improvement of patient outcomes, procedural efficiency, ... ... ...
(Date:10/4/2017)... , Oct. 4, 2017  According to the Centers for Disease Control ... of October . PhysicianOne Urgent Care is helping communities across ... NY , by offering no-cost* flu shots through the end of ... by certain health insurance regulations. ... best time to get a flu shot is by the end of ...
Breaking Medicine Technology: